Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Jabak Discussed with the Syndicate of Hospitals Owners the Health Sector Issues and Received an Invitation to Attend the Arab Hospitals Forum in Cairo

 
The Minister of Public Health Jamil Jabak received a delegation from the private hospitals owners syndicate headed by Sleiman Haroun, in the presence of MP Fadi Alama. During a meeting, hospitals matters and the ways to find solutions for the problems of the citizens and the hospitals’ owners were discussed.
 
“We consider them as an integral part of the hospitalization sector in Lebanon and a key partner in the health care and medical sector in Lebanon,” Jabak told the delegation.
 
Dr. Jabak said that the meeting tackled the problems of the syndicate and mentioned that the ministry would work to find solutions to these problems in no time.
 
Haroun

Haroun stated that the visit aimed at congratulating Dr. Jabak for taking office at the Ministry. “The meeting provided an opportunity to consider the matters that need to be dealt with on the long term,” Jabak added.
 
“The delegation noticed Minister Jabak’s concern for the hospitals as much as for the patient and the need to provide him with the necessary services. It was agreed to activate the current scientific mechanism related to the admission of the patient to the emergency room at the hospitals in order to prevent any issues that might arise while admission,” Haroun said.
 
“The syndicate’s delegation asked the Minister of Public health to find solutions for the delay in the settlement of the amounts owed to the hospitals,” Haroun added.
 
Arab Hospitals Federation

Jabak then met with a delegation from the Arab Hospitals Federation that invited him to attend the “Arab Hospitals Federation Forum in Cairo” that will be held in conjunction with the Council of Arab Ministers of Health on 27 and 28 February. The delegation also invited him to attend the Arab Hospitals Federation Conference” that will be held next 10 and 11 April in Kuwait.
    1
ATC Name ↓ B/G Ingredients Dosage Form Price
B02BD02 NUWIQ BioTech Coagulation Factor VIII recombinant, human (Simoctogog alfa) - 500IU 500IU Injectable powder for solution+diluent 47,418,699 L.L
G02BA NUVARING B Etonogestrel - 0.12mg/day, Ethinylestradiol - 0.015mg/day Ring 1,052,229 L.L
B05XA31 NUTRYELT G Zinc (gluconate) - 10000mcg/10ml, Copper (gluconate) - 300mcg/10ml, Manganese (gluconate) - 55mcg/10ml, Sodium fluoride - 950mcg/10ml, Iodine potassium iodide - 130mcg/10ml, Selenium (sodium salt) - 70mcg/10ml, Molybdenum (Sodium molybdate) - 20mcg/10ml, Chrome (chlorure) - 10mcg/10ml, Ferrous (gluconate) - 1000mcg/10ml Injectable concentrate for solution 3,483,240 L.L
J05AP08 NUCLEOBUVIR G Sofosbuvir - 400mg 400mg Tablet, film coated 50,670,440 L.L
M09AX NUCLEO C.M.P. FORTE G UTP+UDP+UMP - 3mg, CMP - 5mg Capsule 448,843 L.L
L02BB06 NUBEQA B Darolutamide - 300mg Tablet, film coated 239,808,442 L.L
B01AC06 NU-SEALS G Acetylsalicylic acid - 75mg 75mg Tablet, enteric coated 403,153 L.L
B02BX04 NPLATE BioTech Romiplostim - 250mcg 250mcg Injectable powder for solution L.L
B02BX04 NPLATE BioTech Romiplostim - 250mcg 250mcg Injectable powder for solution 67,369,332 L.L
A04AA01 NOZENTRIX G Ondansetron - 8mg 8mg Tablet, film coated 1,151,865 L.L
A04AA01 NOZAMET G Ondansetron - 4mg 4mg Film, orodispersible 3,234,181 L.L
A04AA01 NOZAMET G Ondansetron - 8mg 8mg Film, orodispersible 6,075,448 L.L
J02AC04 NOXAFIL B Posaconazole - 100mg 100mg Tablet, gastroresistant 62,027,714 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 1mg 1mg (50KIU) Injectable powder for solution+diluent L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 5mg 5mg (250KIU) Injectable powder for solution+diluent 275,483,041 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 1mg 1mg (50KIU) Injectable powder for solution+diluent 60,203,802 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 2mg 2mg (100KIU) Injectable powder for solution+diluent 110,192,388 L.L
A10AB05 NOVORAPID FLEXPEN BioTech Insulin aspart - 100IU/ml 100IU/ml Injectable solution 3,123,090 L.L
A10AB05 NOVORAPID FLEXPEN BioTech Insulin aspart - 100IU/ml 100IU/ml Injectable solution 3,123,090 L.L
A10AB05 NOVORAPID FLEXPEN BioTech Insulin aspart - 100IU/ml 100IU/ml Injectable solution 3,123,090 L.L
A10BX02 NOVONORM B Repaglinide - 1mg 1mg Tablet 571,133 L.L
A10BX02 NOVONORM B Repaglinide - 0.5mg 0.5mg Tablet 475,720 L.L
A10BX02 NOVONORM B Repaglinide - 2mg 2mg Tablet 666,546 L.L
A10AD05 NOVOMIX 30 BioTech Insulin aspart - 30%, Insulin aspart protamine - 70% 100IU/ml Injectable suspension 4,264,012 L.L
A10AD05 NOVOMIX 30 BioTech Insulin aspart - 30%, Insulin aspart protamine - 70% 100IU/ml Injectable suspension 4,264,012 L.L
A10AD05 NOVOMIX 30 BioTech Insulin aspart - 30%, Insulin aspart protamine - 70% 100IU/ml Injectable suspension 4,264,012 L.L
B02BD02 NOVOEIGHT BioTech Turoctocog Alfa - 500IU 500IU Injectable powder for solution+diluent 29,783,973 L.L
A03FA03 NOVADOM G Domperidone - 10mg 10mg Tablet 278,175 L.L
G02CB03 NOSTIFIX G Cabergoline - 0.5mg 0.5mg Tablet 248,611 L.L
G02CB03 NOSTIFIX G Cabergoline - 0.5mg 0.5mg Tablet 976,973 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026